Skip to main content

Advertisement

Table 1 Patient demographics, baseline and study characteristics

From: Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis

Study, year, trial registration, and reference Study characteristics Study duration (weeks) Enrolled patients Treatments and doses Concomitant medications for asthma Disease characteristics Age (years) Male (%) Asthma events (n/day) Previous hospitalization for asthma (%) FEV1 (% predicted) Jadad score
Calzetta et al., 2018, DOROTHEO 1, ISRCTN65297911, http://www.isrctn.com/ISRCTN65297911, [8] Multicentre, double-blind, randomized, placebo-controlled, parallel-group 12 346 Doxofylline 200 mg t.i.d., doxofylline 400 mg t.i.d., theophylline 250 mg t.i.d., placebo Salbutamol as needed FEV1 ≥ 50 and < 80%, ≥15% post-bronchodilator increase in FEV1 36 49 1.2 40 66 5
Calzetta et al., 2018, DOROTHEO 2, ISRCTN65297911, http://www.isrctn.com/ISRCTN22374987, [8] Multicentre, double-blind, randomized, placebo-controlled, parallel-group 12 220 Doxofylline 400 mg t.i.d., theophylline 250 mg t.i.d., placebo Salbutamol as needed FEV1 ≥ 50 and < 80%, ≥15% post-bronchodilator increase in FEV1 37 45 1.0 42 67 5
Lal et al., 2015, NA, [10] Single-centre, open, parallel-group 8 30 Doxofylline 200 mg b.i.d., theophylline 200 mg b.i.d. Standard treatment NA 35 NA NA NA NA 1
Margay et al., 2015, NA, [9] Single-centre, open, randomized, parallel-group 6 100 Doxofylline 400 mg b.i.d., theophylline 300 mg b.i.d. Salbutamol as needed FEV1 ≥ 50% and ≤ 80%, ≥12% post-bronchodilator increase in FEV1 38 45 1.7 NA 68 3
  1. FEV1 forced expiratory volume in 1 s, NA not available